UBS lowers Amgen stock price target to $430 on drug trial concerns
UBS lowers Amgen stock price target to $430 on drug trial concerns Investing.com Canada
Covered in this story
Dalsna Finance is currently tracking 48 stories mentioning Amgen, the earliest published 26 May 2026.
Summary aggregated from Investing.com Canada's public RSS feed. The full reporting belongs to Investing.com Canada — please read it on their site.